REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study
Clinical trial NCT02366026 · UNKNOWN
Trial details
- NCT number
- NCT02366026
- Sponsor
- Immune Response BioPharma, Inc.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-01
- Primary completion
- 2019-06-01
- Enrollment
- 500
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.